Nirrin’s TALOS™: A Bet on Execution Over Estimation in Protein Analytics

BILLERICA, MA – June 03, 2026 – In the high-stakes world of biopharmaceutical manufacturing, precision is not just a goal; it's a prerequisite. Every step, from early process development to final release testing, hinges on accurate data. For decades, a foundational measurement—protein quantitation—has relied on methods that, while established, are fraught with operational complexity and potential inaccuracies. Now, Billerica-based Nirrin Technologies is making a bid to overhaul this critical workflow with the commercial launch of TALOS™, a direct protein quantitation system that promises to replace workflow burdens with analytical rigor.

The system is built on the company's proprietary High-Precision Tunable Laser Spectroscopy (HPTLS™) and aims to sideline the industry-standard UV-based workflows. “As biologics manufacturing becomes more distributed, automated, and data-driven, the need for consistent, transferable protein quantitation across workflows and facilities becomes increasingly important,” said Bryan Hassell, Ph.D., CEO of Nirrin Technologies, in the company’s announcement. “TALOS™ is designed for modern biologics manufacturing.” The claim is bold: a simpler, more reliable, and transferable approach. For an industry wrestling with accelerating timelines and increasing complexity, this is a solution worth analyzing.

Deconstructing the Bottleneck

To understand the potential impact of TALOS™, one must first appreciate the persistent challenges of its predecessors. The workhorse of protein quantitation has long been UV-Vis spectroscopy, typically measuring absorbance at a wavelength of 280 nm. The method is fast and non-destructive, but its Achilles' heel is its principle: it measures the presence of aromatic amino acids like tryptophan and tyrosine. This makes the measurement inherently dependent on the specific composition of the protein and highly susceptible to interference from other UV-absorbing impurities.

More critically, UV-Vis has a limited linear range. As protein concentrations increase dramatically through downstream processing, labs are forced into a routine of serial dilutions. This isn't just a minor inconvenience; it's a significant source of error, time consumption, and sample waste. “Every time a technician performs a dilution, you introduce a variable, a potential for pipetting error that can cascade through your calculations,” noted one senior process scientist from a major biopharma firm. “We’ve spent years trying to engineer that variability out of our processes, and here it is, right in one of our most fundamental measurements.”

Variable pathlength UV systems were developed to mitigate the dilution issue, but they introduce their own mechanical complexity with moving optical components and slope-based calculations. Alternative methods, such as colorimetric assays, are often slow and even more prone to interference from common buffer components. The result is a patchwork of analytical methods, each with compromises, making it difficult to achieve consistent data from the low concentrations at harvest to the highly concentrated final drug substance. This inconsistency is a major hurdle for method transfer between development and manufacturing, or across different global sites.

A Spectroscopic Shift: How HPTLS™ Changes the Game

Nirrin’s TALOS™ system sidesteps these issues by fundamentally changing both the light source and the target of measurement. Instead of relying on a broad-spectrum lamp, the proprietary HPTLS™ technology uses a high-precision tunable laser. This provides a more powerful and focused light source that enables higher sensitivity. But the real innovation lies in what it measures.

TALOS™ operates in the near-infrared (NIR) spectrum, targeting the molecular vibrations of the peptide backbone itself—the fundamental structure common to all proteins. This approach immediately decouples the measurement from the variable content of aromatic amino acids, making it more robust and less molecule-specific. It also inherently reduces interference from many common process-related impurities.

Furthermore, the system employs a fixed 1 mm optical pathlength. This design choice eliminates the moving parts and mechanical adjustments of variable pathlength systems, a key source of operational variability. By fixing the pathlength, Nirrin aims to deliver repeatable performance across users, sites, and deployment configurations. The result is a system that can quantify protein concentrations from a remarkably low 0.1 mg/mL up to a high-concentration formulation of 250 mg/mL, all from a single 15 µL sample, in seconds, and without any dilution.

This unprecedented dynamic range means a single analytical platform can potentially serve the entire bioprocess workflow, from upstream harvest samples to downstream final product. The operational simplicity—no dilutions, no moving parts, no molecule-specific calibration—directly addresses the core pain points that have plagued manufacturing teams for years.

From the Lab to the Line: A Tool Built for Manufacturing

An innovative technology is only as good as its execution in a real-world environment. Nirrin Technologies appears to have designed TALOS™ with the stringent demands of GMP manufacturing at the forefront. The promise of a consistent quantitation architecture is key for transferability. A method developed in a process development lab in one country should, in theory, perform identically in a GMP manufacturing suite on another continent. TALOS™ aims to make this a practical reality.

Crucially, the system is delivered with GMP-aligned, 21 CFR Part 11–capable software. For those outside the industry, this might seem like a footnote, but for any company producing commercial therapeutics, it is a non-negotiable requirement. 21 CFR Part 11 governs the use of electronic records and signatures, ensuring data integrity through features like secure access, unalterable audit trails, and system validation. By building these capabilities into the platform, Nirrin is removing a significant barrier to adoption for regulated commercial manufacturing.

The initial launch is for an at-line configuration, where a sample is drawn from the process and analyzed on a nearby instrument. However, the company’s roadmap includes in-line flow cells and in-situ probes, which are currently in development. This forward-looking plan signals a clear understanding of where the industry is headed.

Nirrin's Broader Play for Bioprocess 4.0

The launch of TALOS™ is not an isolated event; it is a strategic piece in Nirrin’s larger vision to enable the data-driven, automated 'factory of the future.' It joins the company’s Atlas™ system, which also leverages HPTLS™ for real-time process monitoring. This portfolio approach, backed by a 2021 strategic investment from Gamma Biosciences, suggests a concerted effort to become a key technology provider for Biopharma 4.0 and continuous manufacturing initiatives.

Further evidence of this long-term strategy came in March 2025 with the granting of a U.S. patent for Nirrin’s advanced flow-cell technology. This intellectual property, focused on precise temperature control and optical path management, directly supports the development of the in-line and in-situ configurations that will allow for true real-time process monitoring without sampling. Such capabilities are foundational to implementing Process Analytical Technology (PAT), a framework encouraged by regulators to build quality into products by monitoring processes in real time.

By providing a tool that promises to deliver fast, reliable, and transferable data, Nirrin is offering a key enabler for advanced process control and automation. The challenge, of course, will be convincing a cautious and heavily regulated industry to move away from decades-old, albeit flawed, methods. Yet, by focusing on the tangible benefits of operational simplicity, data consistency, and built-in compliance, Nirrin is making a compelling case that the time for estimation is over, and the time for precise execution is now.